Essentra (LON:ESNT – Get Free Report) had its price target lowered by equities researchers at Berenberg Bank from GBX 255 ($3.41) to GBX 200 ($2.68) in a note issued to investors on Tuesday, Digital Look reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price objective suggests a potential upside of 32.80% from the stock’s current price.
A number of other equities analysts have also weighed in on the company. Jefferies Financial Group lowered their target price on Essentra from GBX 260 ($3.48) to GBX 250 ($3.35) and set a “buy” rating on the stock in a research note on Friday, July 12th. Deutsche Bank Aktiengesellschaft reduced their price target on Essentra from GBX 240 ($3.21) to GBX 200 ($2.68) and set a “buy” rating on the stock in a research report on Tuesday, September 17th.
View Our Latest Analysis on Essentra
Essentra Stock Performance
Insider Buying and Selling
In other Essentra news, insider Scott Fawcett bought 10,479 shares of Essentra stock in a transaction on Wednesday, September 18th. The shares were purchased at an average price of GBX 142 ($1.90) per share, with a total value of £14,880.18 ($19,925.25). 0.93% of the stock is currently owned by company insiders.
About Essentra
Essentra plc manufactures and distributes plastic injection and vinyl dip moulded, and metal components worldwide. The company offers cable ties and conduit, and accessories; grommets, strain relief, and blanking plugs; cable glands and accessories; caps and plugs; card guides and pullers; circuit board hardware products; EMI suppression ferrite cores; fan accessories comprising filters and fan mounting accessories; screws and nuts; rivet and panel fasteners; barbed and push-fit fasteners; binder screws and snap fasteners; washers; spacers; brushes; feet; fibre management; and furniture fittings.
Read More
- Five stocks we like better than Essentra
- How to Invest in the Best Canadian Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Essentra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Essentra and related companies with MarketBeat.com's FREE daily email newsletter.